The effect of empagliflozin on growth differentiation factor 15 in patients with heart failure: a randomized controlled trial (Empire HF Biomarker)

Autor: Massar Omar, Jesper Jensen, Caroline Kistorp, Kurt Højlund, Lars Videbæk, Christian Tuxen, Julie H. Larsen, Camilla F. Andersen, Finn Gustafsson, Lars Køber, Morten Schou, Jacob Eifer Møller

Publikováno v: Cardiovascular Diabetology, Vol 21, Iss 1, Pp 1-12 (2022)

Abstract Background Plasma growth differentiation factor-15 (GDF-15) biomarker levels increase in response to inflammation and tissue injury, and increased levels of GDF-15 are associated with increased risk of mortality in patients with heart failur

Externí odkaz: https://doaj.org/article/655ef519868a42d5b17b7fd6d353a298

The effect of empagliflozin on contractile reserve in heart failure: Prespecified sub-study of a randomized, double-blind, and placebo-controlled trial

Autor: Jesper Jensen, Massar Omar, Mulham Ali, Peter H. Frederiksen, Caroline Kistorp, Christian Tuxen, Camilla F. Andersen, Julie H. Larsen, Mads Kristian Ersbøll, Lars Køber, Finn Gustafsson, Jens Faber, Julie Lyng Forman, Jacob Eifer Møller, Morten Schou

Publikováno v: Jensen, J, Omar, M, Ali, M, Frederiksen, P H, Kistorp, C, Tuxen, C, Andersen, C F, Larsen, J H, Ersbøll, M K, Køber, L, Gustafsson, F, Faber, J, Forman, J L, Møller, J E & Schou, M 2022, ' The effect of empagliflozin on contractile reserve in heart failure : Prespecified sub-study of a randomized, double-blind, and placebo-controlled trial ', American Heart Journal, vol. 250, pp. 57-65 . https://doi.org/10.1016/j.ahj.2022.04.008

Background: Sodium-glucose co-transporter-2 inhibitors improve cardiac structure but most studies suggest no change in left ventricular (LV) systolic function at rest. Whether sodium-glucose co-transporter-2 inhibitors improve LV contractile reserve

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc04bac3f7a53c2c532fd3c77cc10b84
https://pubmed.ncbi.nlm.nih.gov/35513022